Using MRI to improve diagnosis of brain damage from lung cancer treatment
Contribution of the CEST Sequence in the Characterization of Radionecrosis of Brain Metastases of Pulmonary Origin
This study tests a new MRI method to see if it can better diagnose brain damage in lung cancer patients who have had radiation treatment and are facing complications.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Drugs / interventions | Bevacizumab, chemotherapy, immunotherapy |
| Locations | 1 site (Paris) |
| Trial ID | NCT05977803 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the effectiveness of the Chemical Exchange Saturation Transfer (CEST) MRI sequence in diagnosing radionecrosis in patients with brain metastases originating from lung cancer. It compares the diagnostic performance of CEST with the standard T2* infusion method following contrast injection. The study focuses on patients who have undergone stereotactic radiotherapy for brain metastases and are experiencing complications related to treatment. By improving diagnostic accuracy, the study seeks to enhance patient management and treatment outcomes.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 with histologically confirmed lung cancer and brain metastases who have received radiotherapy.
Not a fit: Patients who are contraindicated for MRI or have severe cognitive impairments that prevent informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate diagnoses of radionecrosis, allowing for better-targeted treatments for patients with brain metastases from lung cancer.
How similar studies have performed: While there have been various studies on MRI techniques for diagnosing brain metastases, the specific use of the CEST sequence for radionecrosis is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients \> 18 years of age * Histologically proven primary lung cancer * Histologically proven or not brain metastases * Irradiated metastases * Inclusion in a treatment protocol for brain metastases by brain metastasis in toto or stereotactic or gamma-knife radiotherapy * Morphological increase of one or more lesions of secondary brain metastases on a follow-up MRI * Patients affiliated to a social security scheme Exclusion Criteria: * Opposition to the study * Contraindication to MRI * Refusal of imaging by the patient * Patient with state medical aid (unless exemption from affiliation) * Severe cognitive impairment making informed consent impossible * Patients under guardianship or deprived of liberty
Where this trial is running
Paris
- Hôpital Bichat-Claude Bernard — Paris, France (Recruiting)
Study contacts
- Principal investigator: Augustin Gaudemer, MD — Assistance Publique - Hôpitaux de Paris
- Study coordinator: Augustin Gaudemer, MD
- Email: augustin.gaudemer@aphp.fr
- Phone: 01 40 25 76 13
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.